Advertisement
open access
Medical Conferences
Conference Reports
Conference Proceedings
Other Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
2024 Medicom Conference Planning
Conference Proceedings
Home
>
Neurology
>
MSMilan 2023
MSMilan 2023
9th Joint ECTRIMS
–
ACTRIMS Meeting
11
–
13 October 2023 Milan, Italy
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany
Real-world data supports ocrelizumab prior to conception
Presented By
Dr Wei Yeh, Alfred Health and Monash University, Australia
MSMilan 2023 Highlights Podcast
Presented By
Dr Rachel Giles, Medicom
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Presented By
Dr Christine Lebrun-Frenay, CHU de Nice, France
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Presented By
Dr Yi Chao Foong, Monash University, Australia
Paediatric MS
Prioritising high efficacy therapies in children with MS
Presented By
Dr Nail Benallegue, Nantes University, France
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
Presented By
Dr Vinicius Schoeps, University of California, CA, USA
NMOSD & MOGAD
An update on evolving treatment algorithms for NMOSD and MOGAD
Presented By
Prof. Jeffrey Bennett, University of Colorado, CO, USA
Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause
Presented By
Dr Alyssa Nylander, University of California, CA, USA
Real-world data supports ocrelizumab prior to conception
Presented By
Dr Wei Yeh, Alfred Health and Monash University, Australia
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis
Presented By
Prof. Thomas Berger, Medical University of Vienna, Austria
COVID-19 infection associated with higher MS relapse rate
Presented By
Mr David Levitz, Monash University, Australia
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Presented By
Dr Maria Petracca, Sapienza University of Rome, Italy
Curing MS
Understanding what an MS cure means and what it takes
Presented By
Prof. Stephen Hauser, University of California, CA, USA
Prodromal MS
Progressive brain tissue loss precedes the onset of clinical MS by years
Presented By
Dr Christina Azevedo, University of Southern California, CA, USA
Sickness absence rate increases years before clinical onset of MS
Presented By
Dr Ali Manouchehrinia, Karolinska University, Sweden
Treatment Trials and MS Strategies
Early intensive treatment enhances long-term clinical outcomes
Presented By
Dr Pietro Iaffaldano, University of Bari, Italy
Anti-CD40L antibody safe and effective in a phase 2 study
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Presented By
Dr Tomoko Okamoto, National Center Hospital, Tokyo, Japan
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Presented By
Prof. Amit Bar-Or, University of Pennsylvania, PA, USA
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Presented By
Prof. Vincent Van Pesch, UCLouvain, Belgium
Biomarkers & Imaging
Retinal OCT markers hold promise for early MS diagnosis
χ-separation can assess the effects of tissue destruction in early MS lesions
Presented By
Dr Jannis Müller, University of Basel, Switzerland
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity
Presented By
Dr Pascal Benkert, University Hospital Basel, Switzerland
Broad rim lesions correlate with a rapidly progressive MS phenotype
Presented By
Dr Jussi Lehto, University of Turku, Finland
Smouldering inflammation detectable even in the earliest stages of MS
Presented By
Dr Markus Matilainen, University of Turku, Finland